containing myo - Inositol for improving metabolic syndrome for women

metabolic sydrome is a cluster of conditions — increased blood pressure, a high blood sugar level, excess body fat around the waist and abnormal cholesterol levels. "metabolic syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke. the term "metabolic" refers to the biochemical processes involved in the body's normal functioning." (source: 1)

 

 

 

 

containing myo - Inositol for Fertility

 

it all starts with an healthy egg. to become pregnant, a women needs a regular menstrual cycle, regular ovulation and a healthy oocyte (egg).  the follicular micro-environement is an important determinant of oocyte development based on the findings of one important study (source: 2). the study concludes: „we propose that higher concentrations of myo – Inositol and estradiol in human follicular fluid appear to play a role in follicular maturation and provide a marker of good quality oocytes.“ myo – Inositol in combination with Folic Acid (the Vitamin B6) has demonstrated in clinical studies a significant improvement in testosterone, triglyceride and insulin levels, an important step to increase the chances of pregnancy (source: 3). INOCAPS® can be used three times daily and as a result it improved the quality of oocytes and ovulation was more regular.

 

 

 

 

 

containing myo - Inositol for relief of polycystic ovarian syndrome (PCOS)

 

one form of metabolic syndrome in women is called PCOS effecting around 20% of all women of childbearing age (source: 4). PCOS leads to elevated testosterone levels and a decrease in regular ovulation with viable eggs. These PCOS women in particular can benefit from taking myo - Inositol as a food supplement in combination with Folic Acid twice daily as in clinical studies proven.

 

In one Italian study conducted in 2007, researchers followed 25 women with oligo-amenorrhea (irregular menses) or amenorrhea (no menses) diagnosed with PCOS. myo - Inositol and folic acid were given daily (like INOCAPS®). Those treated had at least one menstrual cycle, and of these, seventy two percent continued ovulating normally. Forty percent of the women became pregnant and the study concluded that, “myo-Inositol is a simple and safe treatment that is capable of restoring spontaneous ovarian activity and consequently fertility in most patients with PCOS. this therapy did not cause multiple pregnancy.” (source: 5).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

containing folic acid for protection of unborn against neural tube defects (NTD)

NTDs are birth defects of the brain, spine, or spinal cord. they happen in the first month of pregnancy, often before a woman even knows that she is pregnant. (source 6) poor folic acid status in the peri-conceptual period has been associated with increased risk of NTD in the offspring. poor folate status may also lead to hyperhomocysteinaemia, which has been associated with and increased risk of vascular disease. (source 7) 

according to the world health organisation, women should take 0.4 mg per day two months before conception and during the first three months of their pregnancy to reduce the risk of a NTD affected pregnancy.  (source 8)

if INOCAPS® is used three times daily, the women protects her unborn sufficiently against NTD reaching the recommended dose.

 

now available in Denmark, Finland, Iceland and Sweden

 

INOCAPS® is an affective food supplement - free of hormones, free of worries - pure natural! It can be ordered in your pharmacy or convenient  at our eShop. 

 

Sources:

 

1. http://www.nhlbi.nih.gov/health/health-topics/topics/ms

2. Chiu T. et al. Follicular fluid and serum concentrations of Myo – Inositol in patients undergoing IVF: relationship with oocyte quality. Human Reproduction 2002;17(6): 1591-1596

3. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003;7(6):151–159

4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9): 3078–3082

5. http://www.ncbi.nlm.nih.gov/pubmed/17952759

6. http://www.nlm.nih.gov/medlineplus/neuraltubedefects.html

7. http://europa.eu.int/comm/food/fs/sc/scf/index_en.html 

8.  http://www.ifglobal.org/en/what-we-do/prevention